NEW DRUG / REGULATORY UPDATE
Last reviewed: 15 September 2026
On 3 September 2026, the U.S. Food and Drug Administration (FDA) approved Zanvastro (zilganersen) for paediatric and adult patients with Alexander disease. According to the FDA, it is the first approved treatment for this rare neurological disorder and the first designed to address its underlying GFAP-related protein accumulation.
What is Alexander disease?
Alexander disease is a very rare, progressive neurological disorder associated with disease-causing variants in the gene encoding glial fibrillary acidic protein (GFAP). Abnormal GFAP accumulates in supportive cells of the central nervous system and can lead to developmental loss, seizures, weakness, walking difficulty and other serious complications. Clinical presentation varies substantially by age and patient.
How zilganersen is intended to work
Zilganersen is an antisense oligonucleotide. The FDA describes it as reducing production of abnormal GFAP before the protein can accumulate further. This mechanism is disease-directed, but it should not be interpreted as a guaranteed cure or reversal of established neurological injury.
Evidence reviewed by the FDA
The FDA based its decision on a multicentre, randomised controlled study registered as NCT04849741, involving 49 patients aged two years and older, plus an open-label substudy of four children younger than two years.
For participants aged five years and older who had measurable walking difficulty at baseline, the FDA reported better walking speed at 61 weeks with treatment than with no treatment. In children aged two to four years, a broader motor assessment was used; treated children improved while controls declined. These outcomes cannot automatically be generalised to every patient or every disease manifestation.
Important limitations and uncertainty
- Alexander disease is extremely rare, so the clinical programme was small.
- Evidence in children younger than two years included only four treated patients and relied partly on pharmacokinetic modelling.
- Long-term durability, rare adverse effects and outcomes across the full clinical spectrum will require continued follow-up and post-marketing evidence.
- The FDA announcement reports a U.S. approval. It does not establish approval, pricing or availability in India; those questions require current CDSCO and manufacturer information.
Safety information
The FDA lists vomiting, back pain, cough, headache and post-lumbar-puncture syndrome among the most common adverse effects. Aseptic meningitis has also been reported. Treatment decisions require specialist assessment and review of the full prescribing information; this article does not provide dosing or administration instructions.
Official and primary sources
- FDA approval announcement (3 September 2026)
- ClinicalTrials.gov record NCT04849741
- CDSCO approved-new-drugs portal
Related reading
Medical disclaimer: This is a regulatory news explainer for healthcare education. It is not individual medical advice and should not be used to start, stop or select treatment. Clinicians should consult the current regulator-approved prescribing information and relevant specialist guidance.
Featured photo credit: National Cancer Institute / Unsplash.